Predictive values of human papillomavirus E6/E7 mRNA test in the prognosis of cervical epithelial neoplasm 1

doi:10.3877/cma.j.issn.1673-5250.2018.01.007

Objective

To evaluate the predictive values of human papilloma virus (HPV) E6/E7 mRNA test in the prognosis of patients with cervical intraepithelial neoplasia (CIN) 1.

Methods

From July 2013 to October 2014, a total of 107 cases of patients who were initially diagnosed as CIN1 by pathologic results of colposcopic cervical biopsy in Department of Gynecology, Yantaishan Hospital of Yantai were selected as research subjects. All subjects received cervical ThinPrep liquid-based cytology test (TCT), HPV DNA genotyping test and HPV E6/E7 mRNA test within one month prior to initial diagnosis of CIN1. Two-year follow-ups and once every six months were conducted on all subjects, including the re-examination of TCT, HPV DNA genotyping test and HPV E6/E7 mRNA test. And cervical biopsies were conducted on suspicious lesions. According to the results of TCT, HPV DNA genotyping test, HPV E6/E7 mRNA test and colposcopic cervical biopsy at the end of follow-up, all subjects were enrolled into negative group and continuous or progressive group, respectively. Chi-square test was used to compare the positive rates of HPV E6/E7 mRNA between two groups. Mann-Whitney U rank sum test was used to compare expression levels of HPV E6/E7 mRNA between two groups. The sensitivities and specificities of these three cervical screening methods in predicting the prognosis of CIN1 were calculated respectively. Then receiver operator characteristic (ROC) curve of HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 was drawn, and the area under ROC curve (ROC-AUC) was calculated.The optimal critical value of HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 was obtained when the Youden index reaching the maximum value.And its sensitivity and specificity were calculated. This study was approved by the Ethics Committee of Human Beings in Yantaishan Hospital of Yantai and informed consent of clinical research has been signed with every subject.

Results

①According to the results of TCT, HPV DNA genotyping test, HPV E6/E7 mRNA test and colposcopic cervical biopsy at the end of follow-up, all subjects were enrolled into negative group (n=63, the results of TCT, HPV DNA genotyping test and HPV E6/E7 mRNA test all were normal or the colposcopic cervical biopsy result was negative at the end of follow-up) and continuous or progressive group (n=44, the colposcopic cervical biopsy result was CIN1 or higher grade at the end of follow-up). There were no statistically significant differences between two groups in basic clinical data such as age and etc. (P>0.05). ②The positive rate of HPV E6/E7 mRNA and median expression level of HPV E6/E7 mRNA were 61.9% (39/63) and 3 738.4 copy/mL in continuous or progressive group, which were significantly higher than those in negative group (81.8%, 36/44) and 583.5 copy/mL, respectively), and both the differences were statistically significant (χ²=4.901, P=0.027; U=821.000, P<0.001). ③According to the results of two-year follow-up, the continuous or progressive rate of CIN in patients with HPV-16/18 positive was 50.8% (31/61), which was significantly higher than that in patients with HPV-16/18 negative (28.3%, 13/46), and the difference was statistically significant (χ²=5.512, P=0.019). The continuous or progressive rate of CIN in patients with HPV E6/E7 mRNA positive was 48.0% (36/75), which was significantly higher than that in patients with HPV E6/E7 mRNA negative (25.0%, 8/32), and the difference was statistically significant (χ²=4.901, P=0.027). The sensitivities of TCT, HPV DNA genotyping test and HPV E6/E7 mRNA qualitative test in predicting the prognosis of CIN1 were 50.0%, 70.5%, 81.8%, and the specificities were 66.7%, 52.4%, 38.1%, respectively. ④The results of ROC curve analysis of HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 showed that the ROC-AUC was 0.704 (95%CI: 0.601-0.806, P<0.001), and the optimal critical of value HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 was 2 724.0 copy/mL, and the sensitivity of HPV E6/E7 mRNA expression level in predicting continuous or progression of CIN was 54.5%, and the sensitivity was 81.0%.

Conclusions

The sensitive of HPV E6/E7 mRNA qualitative test in predicting the prognosis of CIN1 is relatively high, while the specificity of HPV E6/E7 mRNA quantitative test in predicting the prognosis of CIN1 is relatively high. HPV E6/E7 mRNA test may has clinical values in predicting the prognosis of patients with CIN1.

Key words: Cervical intraepithelial neoplasia, Human papillomavirus, Papillomavirus E7 proteins, Genotyping, Prognosis, Female

表1 2组患者确诊为CIN1时的HPV E6/E7 mRNA阳性率及其表达水平比较

组别	例数	HPV E6/E7 mRNA阳性[例数(%)]	HPV E6/E7 mRNA表达水平[copy/mL，M(P₂₅～P₇₅)]
转阴组	63	39(61.9)	583.5(0～2 148.3)
持续或进展组	44	36(81.8)	3 738.4(784.6～7 277.2)
检验值	?	χ²＝4.901	U＝821.000
P值	?	0.027	<0.001

表1 2组患者确诊为CIN1时的HPV E6/E7 mRNA阳性率及其表达水平比较

组别	例数	HPV E6/E7 mRNA阳性[例数(%)]	HPV E6/E7 mRNA表达水平[copy/mL，M(P₂₅～P₇₅)]
转阴组	63	39(61.9)	583.5(0～2 148.3)
持续或进展组	44	36(81.8)	3 738.4(784.6～7 277.2)
检验值	?	χ²＝4.901	U＝821.000
P值	?	0.027	<0.001

表2 不同宫颈病变筛查方法对CIN1患者预后的预测效果分析[例数(%)]

宫颈病变筛查方法		例数	CIN1预后情况		χ²值	P值
宫颈病变筛查方法		例数	持续或进展	转阴	χ²值	P值
TCT		?	?	?	2.994	0.084
?	阳性	43	22(51.2)	21(48.8)	?	?
?	阴性	64	22(34.4)	42(65.6)	?	?
HPV DNA基因		?	?	?	5.512	0.019
?	分型检测	?	?	?	?	?
?	HPV-16/18阳性	61	31(50.8)	30(49.2)	?	?
?	HPV-16/18阴性	46	13(28.3)	33(71.7)	?	?
HPV E6/E7		?	?	?	4.901	0.027
?	mRNA检测	?	?	?	?	?
?	阳性	75	36(48.0)	39(52.0)	?	?
?	阴性	32	8(25.0)	24(75.0)	?	?

表2 不同宫颈病变筛查方法对CIN1患者预后的预测效果分析[例数(%)]

宫颈病变筛查方法		例数	CIN1预后情况		χ²值	P值
宫颈病变筛查方法		例数	持续或进展	转阴	χ²值	P值
TCT		?	?	?	2.994	0.084
?	阳性	43	22(51.2)	21(48.8)	?	?
?	阴性	64	22(34.4)	42(65.6)	?	?
HPV DNA基因		?	?	?	5.512	0.019
?	分型检测	?	?	?	?	?
?	HPV-16/18阳性	61	31(50.8)	30(49.2)	?	?
?	HPV-16/18阴性	46	13(28.3)	33(71.7)	?	?
HPV E6/E7		?	?	?	4.901	0.027
?	mRNA检测	?	?	?	?	?
?	阳性	75	36(48.0)	39(52.0)	?	?
?	阴性	32	8(25.0)	24(75.0)	?	?

图1 HPV E6/E7 mRNA表达水平预测CIN1预后的ROC曲线

[1]	魏丽惠，沈丹华，赵方辉，等. 中国子宫颈癌筛查及异常管理相关问题专家共识(二)[J]. 中国妇产科临床杂志，2017, 18(3):286-288.
[2]	Binnicker MJ, Pritt BS, Duresko BJ, et al. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results[J]. J Clin Microbiol, 2014, 52(10):3763-3768.
[3]	徐亚丽，高国生，高志斌，等. 人乳头状瘤病毒E6/E7 mRNA检测在不同程度宫颈病变中的应用与分析[J]. 中国卫生检验杂志，2016, 26(22):3260-3262.
[4]	黄雅琴，孟晓华，高阳，等. 人乳头状瘤病毒E6/E7m RNA检测筛查宫颈病变的价值[J]. 中国卫生检验杂志，2015, 25(1):90-91, 94.
[5]	吴慧卿，叶凤如，黄玉玲，等. HPV E6/E7 mRNA检测在年轻女性宫颈癌筛查及宫颈疾病诊治中的应用价值[J]. 中国妇幼保健，2016, 31(14):2817-2819.
[6]	王璐，王晨阳，王武亮，等. 高危型人乳头瘤病毒E6/E7 mRNA检测对宫颈高度鳞状上皮内病变诊断及随访价值研究[J]. 中国实用妇科与产科杂志，2016, 32(6):580-582.
[7]	Nayar R, Wilbur DC. The Pap test and Bethesda 2014[J]. Cancer Cytopathol, 2015, 123(5):271-281.
[8]	杜彩英，李芳. 人乳头瘤病毒DNA及E6/E7 mRNA检测在宫颈病变诊断中的比较研究[J]. 中国优生与遗传杂志，2015, 23(4):38-40.
[9]	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[10]	庞晓庆，郝敏，赵卫红，等. 宫颈上皮内瘤变管理的进展[J]. 肿瘤学杂志，2014, 20(3):181-185.
[11]	Zhang L, Li Q, Zhao M, et al. Discrepancies between biopsy-based and excision-based grading of cervical intraepithelial neoplasia: the important role of time between excision and biopsy[J]. Int J Gynecol Pathol, 2015, 34(3):221-227.
[12]	Galarowicz B, Jach R, Kidzierska J, et al. The role of mRNA E6/E7 HPV high oncogenic risk expression in colposcopy of cervical intraepithelial neoplasia (CIN)[J]. Przegl Lek, 2012, 69(9):651-657.
[13]	宋艳萍，钱小泉，施赛欧，等. HPV E6/E7 mRNA检测在宫颈癌筛查中的应用价值[J]. 中国优生与遗传杂志，2016, 24(4):25-27, 39.
[14]	应香岚，赵湘婉，吴晨曦，等. 应用TCT标本检测高危HPV E6/E7 mRNA在宫颈病变筛查中的价值[J]. 中国卫生检验杂志，2014, 24(23):3422-3424.
[15]	李晓林，栾少红，陈龙，等. 高危型人乳头瘤病毒E6/E7 mRNA检测在宫颈病变筛查中的应用[J/CD]．中华妇幼临床医学杂志(电子版), 2017, 13(2):156-161.

[1]	Kang Ying, Canying Yang, Fengzhen Liu, Lili Chen, Yanna Liu. Prognostic value of left ventricular myocardial strain in asymptomatic patients with severe aortic stenosis[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 581-587.
[2]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients[J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[3]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors[J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[4]	Siping Zhang, Wei Liu, Pengcheng Ma. Therapeutic effects of lower extremity mild varus alignment after total knee arthroplasty[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 808-817.
[5]	Yuezhou Li, Kongxi Zhang, Xiaohong Li, Zhonghua Shang. Prognostic significance of PUM in gastric carcinoma based on bioinformatics analysis[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 426-432.
[6]	Jun Zhang, Zai Luo, Mingyu Duan, Zhengjun Qiu, Chen Huang. Research progress of prognostic prediction models for gastric cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 456-461.
[7]	Qian Yang, Cuifang Li, Wanqiu Zhang. Analysis of short-term and long-term prognosis and influencing factors of primary liver cancer with spontaneous ruptured hemorrhage after emergency TACE surgery[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 33-36.
[8]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[9]	Bing Pan, Shaocheng Lyu, Xin Zhao, Lixin Li, Ren Lang, Qiang He. Effect of number of dissected lymph nodes on efficacy of pancreaticoduodenectomy for distal cholangiocarcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 608-612.
[10]	Qikun Zhang, Fuchao Shang, Qi Li, Guangming Li, Menglong Wang. Survival benefit of combined splenectomy in patients with liver cancer complicated with portal hypertension after radical resection[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 613-618.
[11]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[12]	Weizhi Zhang, Lianxin Liu. Expression and significance of IPO7 in hepatocellular carcinoma based on bioinformatics analysis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 694-701.
[13]	Yongsheng Li, Jiahe Sun, Shuwei Guo, Yikang Lu, Hongzhou Liu. Short-term postoperative complications and their influencing factors in elderly patients with colorectal cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 962-967.
[14]	Jun Wang, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Libin Suo, Jun Chen, chengli Miao, Chenghua Luo. Retrospective analysis of anesthesia management of massive transfusion patients undergoing retroperitoneal tumor resection[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 844-849.
[15]	Libin Suo, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Jun Wang, Jun Chen, Chengli Miao, Chenghua Luo. Key points of anesthesia management and prognostic factors in patients undergoing primary retroperitoneal paraganglioma resection[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 771-776.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export